Abstract | In 2007, the clinical and research profile of illusions, hallucinations, delusions and related symptoms in Parkinson disease (PD) was raised with the publication of a consensus definition of PD psychosis. Symptoms that were previously deemed benign and clinically insignificant were incorporated into a continuum of severity, leading to the rapid expansion of literature focusing on clinical aspects, mechanisms and treatment. Here, we review this literature and the evolving view of PD psychosis. Key topics include the prospective risk of dementia in individuals with PD psychosis, and the causal and modifying effects of PD medication. We discuss recent developments, including recognition of an increase in the prevalence of psychosis with disease duration, addition of new visual symptoms to the psychosis continuum, and identification of frontal executive, visual perceptual and memory dysfunction at different disease stages. In addition, we highlight novel risk factors -for example, autonomic dysfunction -that have emerged from prospective studies, structural MRI evidence of frontal, parietal, occipital and hippocampal involvement, and approval of pimavanserin for the treatment of PD psychosis. The accumulating evidence raises novel questions and directions for future research to explore the clinical management and biomarker potential of PD psychosis. 
In 2007, consensus recommendations from an international work group redefined the landscape of psychosis in Parkinson disease (PD) 1 . Symptoms of psychosis, such as illusions, hallucinations and delusions, are collectively referred to as 'positive' , carrying the implication of an excess of function or brain activity, in contrast with 'negative' symptoms of deficit. Though all long recognized as nonmotor manifestations of PD, positive symptoms such as illusions, hallucinations and delusions were traditionally considered to be distinct from one another, with different clinical implications. In particular, hallucinations of a person, animal or indefinite object passing through the peripheral visual field (passage hallucinations), misperception of actual stimuli (illusions) and a distinct class of perceptual experiences without visual content but a 'feeling' of someone present (presence hallucinations) were not thought to carry the same clinical significance as formed visual hallucinations of animals, objects or figures. This distinction was reflected in the terminology, whereby illusions and passage and presence hallucinations were described as 'benign' or 'minor' hallucinations.
After reviewing the available evidence, the combined National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH) work group concluded that instead of representing distinct symptom classes, the various phenomena formed a continuum progressing over the course of PD. The typical clinical scenario was of minor phenomena evolving to formed visual hallucinations, with insight initially preserved but lost in later stages, and with delusions and non-visual -for example, auditory, tactile and olfactory -hallucinations also developing
. This spectrum of positive symptoms was termed 'PD psychosis' , and the proposed diagnostic criteria included the chronology of symptoms (occurrence after the onset of PD) and symptom duration (recurrent or continuous for 1 month). The NINDS-NIMH recommendations led to a paradigmatic shift in focus from individual positive symptoms to a symptom continuum, which was further characterized in a series of landmark reviews published in the years that followed [2] [3] [4] [5] [6] [7] [8] . These reviews benchmarked knowledge of PD psychosis in terms of its phenomenology, prevalence, clinical implications, mechanisms, treatment and future research directions, and led to a rapidly expanding literature. In this Review, we reflect on the advances that have been made in the 10 years since the publication of the consensus work group criteria, highlighting key research findings and directions in PD psychosis, and their implications for clinical practice and the neuroscience of PD.
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. The hallucinations tend to occur in conditions of low ambient stimulation, typically when the individual is alone in a quiet environment, are experienced several times a day, and last for seconds to minutes in the early stages of PD psychosis. Evidence that has emerged since the publication of the consensus work group recommendations has helped to further characterize the phenomenology of different PD psychosis stages, and their relationship with the progression of Lewy body pathology
.
Early PD psychosis symptoms
According to a report on the largest series of PD patients with presence hallucinations to date, the 'presence' is seen as an unformed visual shadow or mist in up to onethird of cases, may or may not be recognizable, and can be a persistent or recurrent experience of someone who has just left the room (palinparousia) 11 . An online questionnaire administered to individuals with PD suggested an overall prevalence of 50% for presence and passage hallucinations ('extracampine hallucinations' was used as a collective term for both experiences, although this differs from its classic usage), with individual prevalences of 25% for presence hallucinations and 46% for passage hallucinations 12 . Studies of formed hallucinations in PD have found an association between the cognitive profile and the type of hallucination experienced 13 : patients with PD whose typical hallucinations are of unfamiliar content (for example, unidentified figures) have moreprofound deficits of inhibitory executive function than do patients with hallucinations that are recognized (for example, family members). Additional visual symptoms that are observed in the early stages of PD and might be considered to belong to the psychosis spectrum are listed in TABLE 1.
Later PD psychosis symptoms
As PD progresses, hallucinations in non-visual (auditory, tactile and olfactory) modalities occur alongside visual hallucinations. In one cohort of PD patients without hallucinations at baseline, 60% were experiencing hallucinations in multiple sensory modalities by 10 years of follow-up 14, 15 . These non-visual hallucinations are not confined to end-stage PD dementia; they are also found in patients whose cognition is relatively intact (Mini-Mental State Examination (MMSE) score 24 or 25) 16, 17 . One study has estimated the prevalence of delusions in a PD clinical setting at 16% 18 , rising to 47% in the subset of patients with PD psychosis 18 . Of note, an earlier study of patients with PD psychosis taking part in a clinical trial indicated an even higher prevalence of delusions (76%) 16 . The delusional themes that are identified depend on the assessment instruments used, but they typically encompass sin or guilt, grandiosity, reference, religion, persecution, jealousy, and theft, without prominence of any specific theme 16 . Delusional misidentification syndromes, a specific subset of delusions characterized by pathological familiarity, include the Capgras delusion (the belief that someone familiar has been replaced by an imposter), reduplicative paramnesia (the belief that a room or place has been duplicated and is present at two locations simultaneously) and the mirror sign (failure to recognize oneself in the mirror) 19, 20 .
In patients who have dementia with Lewy bodies (DLB), the prevalence of misidentification syndromes was found to increase with greater cognitive decline (40% for MMSE score >20 compared with 60% for MMSE score <10) 21 . A similar trend was observed in individuals with AD, although the prevalence was lower overall (18% for MMSE score >20 and 28% for MMSE score <10). A smaller-scale study of patients with PD dementia found a 16.7% prevalence of misidentification symptoms, and also noted an association between these symptoms and a specific profile of memory and language deficits 20 .
• 
Assessment scales
Several scales to measure positive symptoms were available in 2007 (REF. 22 ), but none were specifically designed for use in PD. As a result, many of the studies reviewed here used a definition of psychosis spectrum status that was based on a single question item within the Movement Disorder Society United PD Rating Scale (MDS-UPDRS), with a range of 0-4
. New scales have emerged to better capture the diversity of symptoms and for use in clinical trials, including the NorthEast Visual Hallucinations Interview (NEVH-I) 23 and a shortened version of the Scale for Assessment of Positive Symptoms adapted for PD (SAPS-PD) 24 . A test to measure susceptibility to pareidolia has been developed for DLB 25 , and might also have a role in the assessment of early symptoms of PD psychosis.
Frequency and clinical consequences
As concluded by the NINDS-NIMH psychosis work group and related reviews, psychosis spectrum symptoms are common in PD and have important clinical consequences, in particular, an increased risk of dementia, nursing home placement and mortality. Quality of life is also impaired, both overall and in subdomains of emotional well-being, daily living, cognition and bodily discomfort 26 . Recent studies have provided revised prevalence estimates for PD psychosis based on longitudinal study data, and have better characterized the link to poor cognitive outcome.
Prevalence
In early cross-sectional studies, the prevalence of the psychosis spectrum varied depending on which symptoms were included, and which PD population was studied. For example, estimates of complex visual hallucinations ranged from 22-38%, compared with 0-22% for auditory hallucinations 3 . Prevalence estimates from older studies that excluded minor hallucinations required revision after the publication of the consensus guidelines 27 . According to the latest figures, minor phenomena are reported in 42% of patients with very early disease 28 , although this high estimate could reflect recall bias 29 . In a large-scale study (n = 250) that excluded patients with MMSE scores ≤23, the prevalence of PD psychosis was 26% 30 . Longitudinal studies conducted in the wake of the consensus guidelines have established that the prevalence of the psychosis spectrum is time dependent, increasing with the duration of PD 3, [31] [32] [33] . In a study that used detailed phenomenological interviews 31 , 82.7% of patients experienced psychosis spectrum symptoms over a period of 36 months. In another study, which excluded minor hallucinations, 60% of patients had experienced psychosis spectrum symptoms by the end of a 12-year follow-up period 33 . The Parkinson's Progression Markers Initiative (PPMI) reported an increase in the prevalence of psychosis from 3% around the time of PD diagnosis to 10% at 2 years' follow-up 32 .
Risk of cognitive decline
An association between visual hallucinations and the subsequent emergence of dementia was first reported in 2003 (REF. 34) . Patients who reported previous visual hallucinations at study entry had an increased risk of dementia at 8 years (OR 3.1, 95% CI 1.6-6.2). This association has been replicated in several recent studies of shorter follow-up duration. One study 35 found that visual hallucinations and visual illusions at baseline had separate predictive effects for dementia at ~4 years, and another study 36 found that the longitudinal emergence of visual hallucinations -that is, emergence across the duration of the study -increased the risk of dementia at ~6 years. The PRIAMO study of early PD found a decline in cognitive function at 2 years in patients with psychosis spectrum symptoms 37 . The detailed profile of cognitive decline over 1-2 years has been reported in prospective cohorts defined at baseline by the presence or absence of visual hallucinations 38, 39 . A significant group × time Approximate ratings of the Movement Disorder Society United PD Rating Scale (MDS-UPDRS) hallucination/psychosis item are shown on the right of the figure, marking progression through different categories of experience on the continuum. The terms pseudohallucination and hallucinosis are used as synonyms for hallucinations with insight in some psychiatric and neurological traditions, but also have other meanings and were not adopted by the NINDS-NIMH work group 1 .
interaction was found, with a steeper decline across a range of cognitive domains and an increased risk of dementia at follow-up in patients with visual hallucinations. A recent metabolic imaging study of PD-associated mild cognitive impairment (PD-MCI) has also found elevated rates of dementia at 30-month follow-up in patients with visual hallucinations 40 .
Psychosis spectrum symptoms are not the sole predictors of future cognitive decline in PD: a range of factors have been identified, the interrelationship of which has yet to be clarified. According to multivariate analyses 34, 36 , visual hallucinations are independent of other factors, but their predicitive statistical significance is reduced when cognitive measures are included 36 , suggesting that cognition and visual hallucinations are closely related.
Association with motor subtypes
Exploratory and confirmatory cluster analysis of a large PD data set revealed associations between non-tremordominant PD and psychopathology, including hallucinations and cognitive impairment 41 . The association between clinically defined non-tremor subtypes and dementia, but not the association with hallucinations, was replicated in a subsequent study 42 . This discrepancy between studies might be attributable to differences in methodology.
Mechanisms and risk factors
A range of possible mechanisms to explain the psychosis spectrum, including changes in visual function, sleep, medication effects and cognition, were identified by the NINDS-NIMH work group and in related reviews, with unifying models being presented to summarize the proposed interrelationship between these mechanisms [1] [2] [3] .
The eye and low-level vision
The predominantly visual nature of PD psychosis spectrum symptoms points to dysfunction in the visual system, and early studies focused on low-level deficits in colour vision, contrast sensitivity and acuity (reviewed elsewhere 2 ). More recently, evidence has emerged of retinal changes in PD, as measured by techniques such as ocular coherence tomography (OCT) and electroretinography 43 ; however, to date, only one study using such techniques has investigated the retinal associations of the PD psychosis spectrum. In patients with visual hallucinations, OCT revealed thinning of the retinal ganglion cell layer in the dominant eye at both nasal and temporal retinal locations 44 . Such thinning could be the result of a primary process within the eye, or could be secondary to retrograde trans-synaptic degeneration caused by changes in the brain. Thinning was more pronounced in PD psychosis patients without dementia (as measured by MMSE score), pointing to a primary process within the eye.
Visual perception and cognition
Early studies of the psychosis spectrum focused on visual hallucinations, and included patients with a range of severity of what might now be termed PD-MCI. More-recent studies have concentrated on differences in cognitive profiles for specific symptom subtypes, and the cognitive profile of the psychosis spectrum at different stages of global cognitive impairment. TABLE 2 shows a range of cognitive tests that have been repeated in different studies, although the same version of a given test is rarely used by different groups. Most studies investigating visual perception, irrespective of the selection
Box 2 | Psychosis spectrum progression and Braak stage
The fact that illusions, passage and presence hallucinations progress to formed visual hallucinations in Parkinson disease (PD) need not imply that they all have the same underlying mechanism. Evidence has emerged that minor hallucinations and formed visual hallucinations are associated with different sets of risk factors. For example, presence hallucinations have been linked to sleep regulation and somnolence scores, illusions are related to somnolence and motor severity scores 160 , and neurobiological explanations of passage hallucinations implicate dysfunctional brainstem eye movement control mechanisms and subcortical and cortical motion pathways, including dorsal stream areas in the visual parietal lobe 105, 161 . Previous studies of visual hallucinations have linked visual parietal areas to hallucinations in the peripheral visual field 162 (as described for passage hallucinations) and palinopsia (helping to account for palinparousiarecently decribed palinopsia-like presence hallucinations 11 ), and subregions of the intraparietal sulcus are linked to eye movement control 163 . By contrast, formed visual hallucinations are associated with changes in cognition, visual function and affect 160 , probably reflecting cortical involvement in ventral occipitotemporal lobe regions 162 . The onset of minor hallucinations might even precede the development of motor symptoms 28 .
The difference in timing of and risk factors for minor hallucinations and formed visual hallucinations mirrors the Braak progression of Lewy body pathology from brainstem to forebrain systems systems 164 . This observation suggests that symptom progression along the PD psychosis continuum begins with isolated minor experiences, indicating brainstem pathology (pink shading in figure) and its wider impact on subcortical and cortical motion and eye movement control networks, including the visual parietal lobe (arrows -note that dysfunction within these cortical networks does not necessarily imply cortical Lewy body pathology
). Subsequent emergence of visual hallucinations with insight indicates basal forebrain involvement (orange shading) and its wider impact on cortical cholinergic projections (arrows), in particular, projections to the ventral occipitotemporal cortex. Finally, multimodality hallucinations, delusions and loss of insight indicate widespread cortical Lewy body pathology.
criteria (for example, unselected PD-MCI cohorts versus participants selected for higher cognitive function) have shown deficits in the perception of objects, including faces. Similarly, most studies investigating executive function, as measured by the Stroop task, response inhibition and verbal fluency, have found deficits in patients with visual hallucinations.
Deficits in memory and related hippocampal function tests are found in PD patients with visual hallucinations, in both unselected PD-MCI and higher-function groups. These deficits withstand correction for MMSE score, depression and PD stage 45 . Some studies have reported deficits that are specific to visual -as opposed to verbal -memory 46 . Greater memory deficits have also been found for black-and-white visual stimuli than for coloured visual stimuli, perhaps reflecting more-limited encoding of visually impoverished stimuli in patients with visual hallucinations 47 . A transitive inference test thought to measure hippocampal function has uncovered impairments in patients with PD psychosis 48 . TABLE 2 helps to illustrate agreement between studies regarding cognitive functions that are deficient, but it does not reveal whether some cognitive functions show relative sparing. Tests purporting to measure visuospatial function, such as the Benton judgement of line orientation and the Rey complex figure test, are often included in test batteries for PD psychosis, but tend not to show significant differences 46, 49 (although see Katzen et al. 50 for evidence of deficits on the Benton test). The lack of consistent findings could be a test sensitivity issue, as other measures of visuospatial function -for example, the Visual Object and Space Perception (VOSP) number location subtest 47, 51 -have been shown to differ between patients with and without visual hallucinations. Tests examining motion, spatiotemporal aspects of visual perception, and eye movements in the PD psychosis spectrum have not been reported to date, but are of particular relevance given the hypothesized role of dysfunctional motion perception and eye movement control in passage and presence hallucinations.
Minor hallucinations.
Only one study has focused on the cognitive profile associated with minor hallucinations in PD 52 . Compared with patients without psychosis spectrum symptoms, patients with minor hallucinations had no significant differences in verbal memory, verbal fluency or sustained attention. Progressive decreases in cognitive performance were seen across the spectrum from no hallucinations, through minor hallucinations and hallucinations with insight, to hallucinations without insight. The lack of cognitive deficits in patients with minor hallucinations raises the issue of whether the onset of psychosis spectrum symptoms predates measurable cognitive decline. Multimodal hallucinations. One might expect patients with non-visual hallucinations in the later stages of PD to exhibit greater cognitive deficits or a different cognitive profile compared with PD patients with visual hallucinations alone. However, one study that compared patients with visual only and visual plus non-visual hallucinations 50 found no evidence of significant additional decline in the latter group for any of the cognitive domains tested (including verbal memory and verbal fluency). The number of patients with hallucinations in multiple modalities was small (n = 12), so the study might have been underpowered to detect such changes.
Delusions. Only one study has compared cognitive profiles between PD psychosis spectrum patients with hallucinations but not delusions and those with delusions but not hallucinations 18 . Cognitive profiles did not differ significantly between the two groups. Cognitive scores in a range of domains were found to correlate with the severity and number of hallucination modalities (for example, auditory, olfactory somatic and/or visual), but not with the severity and number of delusion modalities (for example, jealousy, grandiosity and/or religious delusions). These findings suggest that cognitive risk factors for hallucinations and delusions might differ. This view is supported by evidence from a study investigating risk factors for a specific delusion (delusional jealousy), where an association was found with dopamine agonist treatment but not dementia, in contrast to hallucinations, where an association was found with dementia but not dopamine agonist treatment 53 .
Neuropathology
Neuropathological studies provide important insights into the distribution of Lewy body pathology at different stages of the PD psychosis spectrum
. The first study to report on this issue found significantly higher Lewy body load in the amygdala and parahippocampal gyrus in patients with visual hallucinations, half of whom met the clinicopathological criteria for PD and half of whom met the criteria for DLB 54 . Subsequent studies have replicated the finding of limbic pathology associated with visual hallucinations 55, 56 , with increased pathology also found in other regions, including the superior and lateral frontal cortex (Brodmann area 8/9), inferior and lateral temporal cortex (Brodmann areas 20 and 21), inferior parietal cortex (Brodmann areas 39 and 40), and cingulate cortex (Brodmann area 24). Visual hallucinations are also linked to higher levels of amyloid and tau pathology in frontal, parietal and hippocampal areas 57 . Only one study has investigated the occipital lobe in patients with visual hallucinations: Lewy body and tau pathologies were found to be absent, and amyloid burden was rated as mild 58 . Unlike patients with PD psychosis who have dementia, those without dementia do not have cortical Lewy body involvement. An early study of PD patients with visual hallucinations and MMSE scores >25 found increased Lewy body load in the basolateral nucleus of the amygdala, but only sparse Lewy bodies in the cortex and hippocampus 59 . Consistent with the lack of cortical involvement, a recent study has found no association between Lewy body, tau or amyloid pathology in frontal, parietal and temporal regions and visual hallucinations after controlling for dementia, but found strong associations with dementia after controlling for visual hallucinations 58 . Such findings suggest that the neuropathological changes underlying visual hallucinations are distinct from those underlying dementia.
Involvement of the cholinergic system in visual hallucinations is suggested by brainstem atrophy in the pedunculopontine nucleus 60 and atrophy of the substantia innominata, which contains the nucleus basalis of Meynert 46 . The cause of the atrophy is unclear, as no association has been found between visual hallucinations and Lewy body, tau or amyloid load in the nucleus basalis of Meynert 58 .
Non-cognitive risk factors
Patients with visual hallucinations exhibit abnormalities on a range of autonomic tests, including the tilt-table test, the Valsalva manouevre and cardiac 123 I-metaiodobenzylguanidine imaging, indicating sympathetic dysfunction 61 . In addition, autonomic dysfunction was found to be an independent risk factor for hallucinations (all modalities included) in PROPARK, a large-scale 5-year prospective study 62 . The same study also reported female sex as an independent risk factor 62 . REM sleep behaviour disorder (RBD) is also associated with visual hallucinations (recently reviewed elsewhere 63 ), although the association is weak 64 , and the proportions of patients with visual hallucinations who do and do not have RBD are similar. Vivid dreams are associated with visual hallucinations after controlling for factors including PD duration, depression, anxiety and UPDRS scores 65 . Depression has been associated with hallucinations in PD 2 . The urinary concentration of the oxidative stress marker 8-hydroxydeoxyguanosine was found to correlate with the hallucination score (modality unspecified) after controlling for MMSE score, age, duration and UPDRS part 3 score 66 .
Dopamine agonists
The role of medication in PD psychosis was noted to be "the most controversial aspect of these criteria" in the 2007 consensus recommendations 1 . Clinical experience suggested that the onset of PD psychosis could be linked to medication onset and improved with dose reduction, but there was no evidence of a direct causal relationship between pharmacological treatments or medication dose and PD psychosis (for example, levodopa infusion did not induce hallucinations 67 ), and PD psychosis was recognized to occur in unmedicated patients.
In the intervening years, the role of medication has received relatively little research attention. The lack of a direct causal role for medication is supported by a high prevalence of minor symptoms 28 or visual hallucinations 68 in drug-naive patients, and the finding that levodopa dose equivalence did not increase the risk of psychosis in some prospective studies 14, 31 , including the PPMI cohort 32 . However, though failing to reach statistical significance, a link to medication is implied in the threefold increase in psychosis onset for patients starting dopamine replacement therapy in the PPMI study. Similarly, a large-scale prospective study identified elevated baseline levodopa dose as a risk factor for PD psychosis, with an odds ratio of 1.26 per 100 mg of dose equivalence increase 33 , and a prospective study of early PD (PRIAMO) found increased rates of dopamine agonist treatment in patients who went on to develop PD psychosis 37 . The PROPARK study also identified dyskinesia and levodopa equivalence measures as independent risk factors for PD psychosis 62 . The NINDS-NIMH work group 1 suggested "antiparkinsons medication as a modifier rather than a necessary feature for the diagnosis of PD psychosis" to help reconcile the medication-related and medicationindependent viewpoints. Evidence that has since emerged supports this 'modifier' account, but highlights the need for further work in this area to clarify the relationship between dopamine replacement therapy and PD psychosis.
Genetics
A recent review of the genetics of psychotic symptoms in PD identified 26 published articles on this topic 69 . The most commonly studied genetic factor is the apolipoprotein E ε4 (APOE*ε4) allele, although dopaminergic pathway genes have been the focus of a number of studies.
With regard to APOE*ε4, little evidence is available to suggest an association with psychotic symptoms in PD (only one of seven studies reported an association with visual hallucinations) [70] [71] [72] [73] [74] [75] [76] , a finding that is mirrored in the AD literature 77 . The extended microtubule-associated protein tau (MAPT) haplotype is less well studied in PD psychosis: an initial study reporting an association between visual hallucinations and the H1 haplotype was not replicated by a second larger study 70, 71 . By contrast, an increasing body of evidence suggests that glucosylceramidase (GBA) mutations are associated with psychosis in PD [78] [79] [80] . Of note, the influence of GBA is not limited to psychosis: GBA, like APOE and MAPT, has been associated with cognition in PD, as well as faster progression to dementia and more-severe motor stages 79, 81 . Any associations between psychosis and these three genes are perhaps most likely to be driven by fundamental disease processes, such as tau or Lewy body accumulation. Therefore, considering any associations with a particular symptom in isolation would be too narrow an approach. Specifically, it will be important to establish whether any subtypes of PD have a pattern of cognitive impairment that is more similar to AD and carries a relatively low risk of psychosis (which might be predicted by APOE), compared with an early dysexecutive syndrome and greater risk of hallucinations (as indicated by the pattern of association with GBA).
Consistent evidence links GBA, but not APOE, with psychosis in PD; however, findings related to other genes have been equivocal. Polymorphisms in dopaminergic pathway genes have been examined in 15 studies
. Although there is some evidence of a relationship between polymorphisms in dopamine transporter and cholecystokinin genes and psychosis, the overall number of studies examining these associations is small, making it difficult to draw reliable conclusions. Research in serotonin (5-hydroxytryptamine, or 5-HT) pathway genes is limited to two studies 82, 83 , but with the recent demonstration of efficacy of pimavanserin for the treatment of PD psychosis (see below), serotonergic genes or other genes in serotonergic signalling pathways may provide promising avenues for future research.
The genetic aetiology of psychosis in PD will be complex, and is likely to involve many genes each with a small effect size. As such, the most promising genetic approaches will probably be those that leverage genome-wide data, which has the advantage of full genome coverage and is not constrained by biases resulting from a priori hypotheses. In the broader literature, recent advances in the analysis of genome-wide data sets have uncovered genetic pleiotropy between clinically distinct diseases 84, 85 . Moreover, analyses whereby biological pathways (for example, molecular, cellular, organ/system or disease) are constructed on
Box 3 | Genetic risk factors for psychosis in Parkinson disease

GBA
Associated with an increased risk of psychosis in three studies [78] [79] [80] . One study including only two cases with hallucinations found no association 165 .
MAPT
Mixed findings: one positive association and one negative 71, 72 .
APOE
No association (in six of seven studies). The APOE*ε4 allele was associated with hallucinations within 5 years of diagnosis in one study [70] [71] [72] [73] [74] [75] [76] .
COMT
No association 74, 166 .
SLC6A3 (also known as DAT1)
Mixed findings: two of three studies reported an association, one with the variable number tandem repeat and one with the 839C>T polymorphism [167] [168] [169] .
DRD2
Mixed findings: one of four studies reported an association 73, 167, 168, 170 .
DRD3
No association 73, 167, 168, 170 .
DRD4
No association 73, 167 .
CCK
Mixed findings: two of four studies show evidence of an association with CCK 45C>T, and one reported a combined effect with the CCKAR CC genotype [171] [172] [173] [174] .
HTR2A
No association 83 .
SLC6A4
One study reported an increased risk associated with the LL genotype in a mixed Lewy body dementia sample 82 .
ACE
Mixed findings: one study reported a significant association with levodopa-induced psychosis, whereas another reported no association 175, 176 .
HOMER1
Mixed findings: one study reported an association with the A allele, and a second reported an association with the G allele and a reduced risk of adverse effects of levodopa treatment 177, 178 . the basis of genomic data and tested for enrichment of single nucleotide polymorphisms in cases versus controls have shown promise in late-life depression 86 . These types of emerging techniques have clear applications in heterogeneous conditions such as PD, where questions surrounding the overlapping aetiology between psychosis across neurodegenerative diseases and psychiatric disorders remain unanswered. The increasing availability of larger, better-characterized data sets will provide greater potential to conduct these more-sophisticated genetic analyses.
Explanatory models
Explanatory models of PD psychosis attempt to integrate risk factors into unifying accounts (reviewed elsewhere 87 ). The Activation-Input-Modulation (AIM) model 88 takes a dimensional approach to PD psychosis, with contributions from an activation factor (the level of arousal), an input factor (the spectrum of externally and internally driven visual percepts), and a modulation factor (neurotransmitter and medication effects). The activation factor may help to explain why hallucinations typically occur with low ambient stimulation. The Perception and Attention Deficit (PAD) model 89 argues that the core mechanism of complex hallucinations is dysfunctional integration of perceptual and attentional processing, leading to the intrusion of generic representations (proto-objects) into perceptual consciousness. In the attentional control model 90 , the core pathology of PD psychosis is dysfunctional integration between three networks (dorsal attention network, ventral attention network and default mode network), with a failure to engage the dorsal attention network in the context of ambiguous visual input and the intrusion of default mode contents into perceptual consciousness [90] [91] [92] . This account is supported by evidence from PD patients with visual hallucinations or illusions of elevated strength of mental imagery 93 , attentional set-shifting deficits 94 , altered resting state and task activation networks 95 , and increased functional connectivity in the default mode network 96 . A dopamine-based model of PD psychosis 97 argues for abnormalities of biasing and gating access to a global workspace that is thought, according to some accounts, to underlie conscious experience.
These unifying models are informed by clinical associations -for example, the combination of visual perceptual and frontal executive deficits -that were recognized at the time that the models were formulated. As the range of risk factors increases, the question arises as to whether all risk factors are linked to the mechanisms underlying PD psychosis. Distinctions may need to be drawn between associations that are integral to the mechanisms of PD psychosis or its individual symptoms, and syndromic associations caused by the spread of PD pathology to neighbouring brain regions or to separate brain regions at a similar disease stage. Which associations and risk factors are integral to PD psychosis and which are syndromic associations is unclear at present, and such information will be pivotal to the development of novel treatment approaches.
Imaging and electrophysiology
The raised profile of PD psychosis, combined with developments in imaging methodology, has resulted in a rapidly advancing evidence base that helps to inform the risk factor and mechanistic accounts of the symptom spectrum.
Structural MRI
Despite methodological differences, structural imaging studies of visual hallucinations have yielded a number of consistent findings [98] [99] [100] . Several studies have reported atrophy in the visual cortex [101] [102] [103] -broadly defined as extending into lateral and ventral occipitotemporal regions including the fusiform gyrus and visual parietal cortex (corresponding to dorsal and ventral visual streams) -although this finding is not univeral 104 . One study of PD patients with and without visual hallucinations (some patients had hallucinations in both visual and other modalities), matched for cognitive status, only detected atrophy in posterior cortical regions 101 , whereas another study of visual hallucinations, in which global cognition (MMSE score) was included as a covariate, found atrophy in frontal, hippocampal and thalamic regions 46 . A study focusing on minor hallucinations found atrophy in the midbrain, cerebellar vermis and visual parietal cortex, as well as areas of increased cortical volume in the limbic cortex and the posterior lobe of the cerebellum, which might be linked to compensatory mechanisms 105 . Studies that did not control specifically for cognition found atrophy of the hippocampal head 106 , frontal regions (particularly the lateral frontal cortex) 103, 107, 108 , cerebellum 103 and lateral parietal cortex 103 in patients with visual hallucinations. The distribution of atrophy described in the various studies is consistent with the profile of cognitive deficits found in PD psychosis (FIG. 1) . At 30-month follow-up, patients who report visual hallucinations at baseline have greater progression of cortical atrophy within limbic, frontal and thalamic regions, and are more likely to have developed dementia 38 . The greater rate of atrophy and hypothesized progression from hippocampal head involvement to diffuse hippocampal atrophy in patients with visual hallucinations 106 might account for the association between visual hallucinations and poor cognitive outcome.
Few studies have investigated white matter changes in PD psychosis. An early study found no differences with regard to a range of clinically defined white matter lesion indices in patients with and without visual hallucinations 109 . A more recent volumetric study described decreased white matter volume in occipital and parahippocampal regions 103 . Another study showed that the microstructural integrity of deep white matter, as measured by fractional anisotropy, was affected in PD psychosis (defined as the presence of perceptual errors, hallucinations in any modality, or delusions). When fractional anisotropy was compared across groups as an absolute measure or normalized to globus pallidus or substantia nigra values, reduced fractional anisotropy was detected within regions of interest in the occipital lobe, frontal lobe and cingulate gyrus, and deep to the left hippocampal head 110 .
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Neurotransmitter imaging
Reduced dopamine transporter binding in the striatum in early PD, as measured by the 123 I-β-CIT tracer, is associated with an increased prospective risk of PD psychosis at 5 years (assessed using the UPDRS thought disorder item) 111 . It is unclear whether this binding reduction represents the underlying mechanism of the psychosis spectrum or is an indirect association, for example, reflecting more-extensive neurodegenerative involvement in PD psychosis.
In a serotonergic imaging study that used the 5-HT 2A receptor ligand 18 F-setoperone, increased binding in ventral occipitotemporal regions and bilateral frontal cortex was identified in patients with visual hallucinations 112 . By contrast, a 5-HT 1A receptor binding study in postmortem tissue found no association with visual hallucinations, although 5-HT 1A binding was elevated in sublayers of the orbitofrontal, ventral temporal and motor cortex in patients with PD, irrespective of visual hallucinations 113 .
Metabolic and blood flow imaging
Occipital hypometabolism and reduced regional cerebral blood flow (rCBF) are characteristics of DLB 114, 115 , and have been linked to visual hallucination severity 116 . Whether the same regions exhibit reduced metabolism and rCBF in PD psychosis is less clear. Metabolic imaging studies of PD patients with and without visual hallucinations have identified reductions in posterior metabolism that spare the occipital pole 117 or primary visual cortex (data from table in Nagano-Saito et al. 118 ). In addition to posterior metabolic deficits, one study found increased frontal metabolism in PD psychosis 118 . Another study found that posterior metabolic deficits were more pronounced in patients with visual hallucinations and cognitive impairment (defined by the K-MMSE cut-off score, the Korean version of the MMSE), but were also present in patients with K-MMSE scores above the threshold value 119 . In contrast to spared occipital metabolism in the studies described above, a recent study of PD-MCI has found evidence of occipital hypometabolism in PD patients with visual hallucinations 40 . The hypometabolism did not differ between patients who did and did not subsequently develop dementia 40 . Evidence also exists of decreased posterior perfusion in 'medicationinduced' hallucinations (mostly visual) that would now be termed PD psychosis, with significant reductions of rCBF in the posterior temporo-occipital cortex but not in the occipital lobe 120 . Similarly, another study of visual hallucinations in PD found trend-level posterior perfusion deficits that spared occipital cortices 121 . A region of decreased perfusion outside the occipital lobe in the ventral temporal cortex (fusiform gyrus) became significant after controlling for confound covariates, as did a region of increased perfusion in the superior and middle temporal gyrus 121 . In summary, consistent evidence points towards posterior changes in metabolism and perfusion in PD patients with visual hallucinations, but the presence or absence of involvement of the occipital lobe remains unclear.
Functional MRI
There is a paucity of data on brain changes occurring in PD at the time of a hallucination (capture studies). One functional MRI (fMRI) case study found a decrease in activity in visual areas coincident with visual hallucinations 122 . This decrease in occipital activity contrasts with evidence from eye disease, schizophrenia and induced visual hallucinations, which indicates that activity in visual areas increases at the time of visual 3) were compared with PD controls (n = 9; mean MMSE score 29.6). A lenient statistical threshold (P < 0.01; 100 contiguous voxels) is used for illustrative purposes. Lighter red shading indicates regions deep to the rendered cortical surface. These summary findings indicate that visual hallucinations in PD are associated with widely distributed but specific regions of cortical atrophy.
hallucinations 123 . The PD case study also reported increased activity in the frontal lobe during the hallucinations 122 . Frontal activations are not found in eye disease and schizophrenia during hallucinations; however, another PD case report, in which a different technique was used (single-photon emission CT with technetium-99m ethyl cysteinate dimer), documented frontal and anterior temporal increases in rCBF during visual hallucinations 124 . Contrasting findings of occipital increases or decreases and the presence or absence of frontal activations across clinical contexts may suggest differences in the underlying mechanisms of hallucinations.
Studies in which visual stimulation was used to probe cerebral activity have reported decreased activation in the parietal lobe, lateral occipitotemporal cortex 125 and occipital cortex 126 in PD patients with a history of visual hallucinations. An early fMRI study reported decreased activity in the primary visual cortex but increased activation in the visual association cortex 127 . In the frontal lobe, both activation increases 125 and activation decreases 126, 128 have been reported in response to visual stimulation. The contrasting findings might relate to differences in the stimuli and tasks used. Reduced occipital low frequency fluctuations have been found in the resting state in PD patients with a history of visual hallucinations 129 . These fluctuations are thought to be an indirect measure of cerebral glucose metabolism and local field potentials, supporting the idea of occipital hypometabolism in patients with PD who are susceptible to visual hallucinations. Increased connectivity between occipital and frontal regions, the striatum and the thalamus 129 and greater co-activation of default mode network nodes in the posterior cingulate/ precuneus and lateral frontal cortex are associated with susceptibility to visual hallucinations in PD 96 .
Electrophysiology
In PD patients with a history of visual hallucinations, the P100 component of visual evoked potentials in response to reversing checkerboard stimulation was found to be delayed 130 , as was the P300 component of a visual oddball task 131 . A delay in evoked potential latency has also been found in association with illusions and visual hallucinations in an immersive virtual reality environment following short-term PD medication deprivation 132 . The evoked potential delays might fall within the distribution of normal variation, however, as rates of retinal and cortical evoked measures categorized as normal or abnormal on the basis of normal population standard deviation cut-off values do not differ between patients with and without hallucinations 132, 133 . Changes in cholinergic-related electrophysiological measures (shortlatency afferent inhibition) associated with susceptibility to visual hallucinations in PD are consistent with a loss of cortical cholinergic input 134 .
Treatment
As outlined in previous reviews, treatment of PD psychosis includes psychological therapies, dose reduction of PD medication, and medication to treat psychosis symptoms 1, 2, 135 . 
Atypical antipsychotics
Evidence for the efficacy of clozapine in PD psychosis [136] [137] [138] sparked interest in the potential efficacy of quetiapine, a structurally related compound. Although early studies suggested a beneficial effect of quetiapine, several subsequent studies failed to replicate the findings in PD 139, 140 and across the spectrum of dementia with parkinsonian symptoms 141 . Similarly, open-label studies suggested that olanzapine was efficacious for PD psychosis, but placebo-controlled 142 and comparative 143 trials found a worsening of motor symptoms without significant improvement of hallucinations. The 2011 Movement Disorder Society evidence-based medicine review of treatments for nonmotor symptoms concluded that there was insufficient evidence on the efficacy of quetiapine, and that olanzapine carried unacceptable risk 135 . Despite the lack of an evidence base, atypical and typical antipsychotics continue to be used in clinical practice 144 , but are associated with increased mortality in the context of clinical trials 145 and a retrospective database analysis, which ranked haloperidol as carrying the highest risk, followed by olanzapine, risperidone and quetiapine 144 . Such evidence cautions against the use of antipsychotics in PD, and highlights the need for further studies in this area, as well as the development of new therapeutic approaches for PD psychosis.
Pimavanserin
The therapeutic effect of clozapine in PD psychosis is thought to relate, in part, to blockade at the 5-HT 2A receptor 146 . A large double-blind, placebo-controlled study of pimavanserin found a significant improvement on the SAPS-PD 147 , with greater improvement in a subgroup with more-pronounced cognitive impairment (Ballard, C. et al., unpublished work, see TABLE 3) . In an earlier study, a global measure of hallucinations assessed as a secondary end point improved in patients treated with pimavanserin, but the reduction in visual hallucinations was not significant when considered separately 146 . The relative lack of efficacy of pimavanserin for visual hallucinations suggests that the wider improvement in psychotic symptoms is mediated by a different subset of 5-HT receptors than those stimulated by lysergic acid diethylamide (LSD), the use of which is associated with predominantly visual phenomena. Pimavanserin received FDA approval in April 2016 for the treatment of PD psychosis. Its adverse event profile to date suggests advantages over other antipsychotics in terms of risk of stroke, falls, fatigue, blood dyscrasia, neuroleptic malignant syndrome, orthostatic hypotension, and worsening of motor symptoms.
Apomorphine
The chemical structure of apomorphine includes a piperidine moiety and, unlike other dopamine agonists, this drug exerts intrinsic antagonist effects at the 5-HT 2A receptor as well as agonist affects at both D1-like and D2-like receptors 148 . This unique profile might account for case report and open-label study evidence that apomorphine does not exacerbate psychosis symptoms and, in some studies, may ameliorate these symptoms 149 or improve visual contrast sensitivity 150 . The mode of apomorphine administration may influence its impact on psychotic symptoms 151 . The open-label EUROINF study found improvements in perceptual and hallucination symptoms in patients treated with either apomorphine or intrajejunal levodopa 152 . The effect size for apomorphine (0.32) was larger than for intrajejunal levodopa (0.29), although the difference was not significant 152 . Apomophine might have a place in the treatment of PD psychosis; however, a better evidence base is needed to guide future recommendations 148, 152, 153 . 
Electroconvulsive therapy
No sham-controlled studies of electroconvulsive therapy (ECT) for PD psychosis have been undertaken, but two case series have reported improvements in PD psychosis spectrum symptoms. In one study (n = 5), Brief Psychiatric Rating Scale scores improved after five to 12 ECT sessions, and the effects persisted for 5-30 weeks 154 . In another study (n = 8), SAPS scores improved at 1 week (longer-term data not reported) after a mean of six ECT sessions 155 .
Systemic illness
Psychosis is part of a range of acute events in PD, and is often seen in hospitalized patients with systemic infection, dopamine agonist withdrawal syndrome or parkinsonismhyperpyrexia syndrome, as well as in postsurgical states 156 . Management of the underlying precipitant, along with rehydration, cautious use of anti psychotic agents and -in suitable cases -gentle introduction of low-dose dopamine agonists, may be required.
Conclusions
The paradigmatic shift in perspective that followed the 2007 consensus definition of PD psychosis revitalized research interest and led to a rapidly expanding literature. The impact of these studies is still evolving, but there have already been important clinical consequences, such as a change in our understanding of the prevalence of PD psychosis, given that it increases with PD duration; expansion of the range of symptoms considered part of the psychosis spectrum; and recognition of new prospective risk factors for PD psychosis. The largest expansion of literature has been in the mechanism domain, particularly in studies of cognitive profile, structural brain imaging and genetics.
Despite substantial progress over the past decade, our current state of knowledge leaves key questions unanswered (BOX 4) . For example, the relationship between PD psychosis, PD-MCI and PD dementia is unclear. Most patients with PD dementia will have psychosis, but only a small proportion of those with PD-MCI have such symptoms. Does this observation imply a difference in PD-MCI cognitive profiles for patients with and without psychosis? If so, an understanding of these profile differences might help to explain the link between early PD psychosis symptoms and the subsequent development of dementia. Another unresolved issue is the relationship between individual symptoms in the PD psychosis spectrum in terms of underlying pathophysiological mechanisms. Evidence from studies of minor hallucinations, formed hallucinations and delusions, for example, suggest that the mechanisms are not the same for all symptoms, with important implications for the assessment of PD psychosis in research studies. A continuum assessment scale might be helpful in epidemiological and risk factor studies, but may be less useful for studying specific symptoms and their underlying mechanism.
Other areas identified as requiring further research include the role of PD medication as a modifier or unmasker of psychosis symptoms, motion perception and eye movement control deficits associated with passage and presence hallucinations, and the transition from hallucinations with insight to those without insight and its impact on quality of life and the move to supervised care. These negative outcomes are arguably the most clinically relevant aspects of PD psychosis; however, the brain changes that underlie them are unclear.
Finally, visual hallucinations are not unique to synucleinopathies, and patients with eye disease, serotonergic dysfunction or AD also have visual symptoms that overlap with those of PD but are associated with different cognitive profiles 157, 158 . The progressive improvement of visual hallucinations in eye disease contrasts with the progressive deterioration in PD and AD psychosis 157, 158 , and comparative studies of brain changes associated with visual hallucination susceptibility across clinical contexts might shed light on why these differences exist.
Overall, two major themes can be recognized in the literature that has emerged over the past decade. One theme highlights the clinical challenges of PD psychosis, with an urgent need for better characterization of its symptoms and their impact, and for evidence on how to assess and treat these symptoms. The second theme highlights what the psychosis spectrum reveals about PD in terms of disease stage and distribution, and its role as a clinical biomarker for PD outcomes. Further research in this area will have implications that extend beyond the symptoms themselves to the wider issues of cognitive decline in PD, patient and carer experience, and the development of novel treatments for positive symptoms in PD and other clinical contexts.
Box 4 | Relationship between brain structure, function and neuropathology in PD psychosis
The relationship between different imaging biomarkers of Parkinson disease (PD) psychosis remains unclear. Areas of reduced posterior cortical metabolism 40 overlap with areas of reduced activation in functional MRI (fMRI) studies 125 , so might reflect similar underlying functional alterations or a causal link (for example, an area of reduced metabolism might result in a reduced blood oxygen level-dependent (BOLD) signal). Likewise, regions of increased metabolic activity in the frontal cortex 118 , as identified in some studies, may relate to regions of increased frontal fMRI activation 125 . One question that arises is why specific subregions of frontal, parietal, limbic and occipital lobes are altered in PD psychosis. Some regions with atrophic or metabolic change have shown increased Lewy body and/or amyloid and tau pathology in postmortem studies [55] [56] [57] . However, other regions, in particular the occipital cortex, have limited neuropathological load even in end-stage disease 58 , contrasting with atrophy and possible hypometabolism in imaging studies. Therefore, in vivo imaging changes may not simply reflect localized neuropathology, but have other causes, for example, loss of cholinergic or serotonergic cortical projections, leading to a specific distribution of receptor upregulation, functional alterations and, in the longer term, atrophy.
